REQUEST A DEMO
Total
USD $0.00
Search more companies

Kolon TissueGene, Inc (South Korea)

Main Activities: Research and Development in the Physical, Engineering, and Life Sciences
Full name: Kolon TissueGene, Inc Profile Updated: July 04, 2023
Buy our report for this company USD 19.99 Most recent financial data: 2022 Available in: English Download a sample report

TissueGene Inc. is engaged in developing of regenerative therapies for the treatment of various orthopedic disorders. The company also develops clinical-stage advanced cell therapies. TissueGene Inc. was founded in 1999. The company is a Maryland-based biopharmaceutical company.

Headquarters
9713 Key West Ave. Suite 300, Rockville, MD 20850, USA
Washington; District of Columbia; Postal Code: 20850

Contact Details: Purchase the Kolon TissueGene, Inc report to view the information.

Basic Information
Total Employees:
Purchase the Kolon TissueGene, Inc report to view the information.
Outstanding Shares:
Purchase the Kolon TissueGene, Inc report to view the information.
Registered Capital:
Purchase the Kolon TissueGene, Inc report to view the information.
Incorporation Date:
June 09, 1999
Key Executives
Purchase this report to view the information.
CEO
Purchase this report to view the information.
CEO
Purchase this report to view the information.
Non-Executive Independent Director
Purchase this report to view the information.
Auditor
Purchase this report to view the information.
Executive Director
Ownership Details
Purchase this report to view the information.
27.3%
Purchase this report to view the information.
17.8%
Purchase this report to view the information.
12.6%
Company Performance
Financial values in the chart are available after Kolon TissueGene, Inc report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
136.22%
Total operating revenue
136.22%
Operating profit (EBIT)
65.24%
EBITDA
67.72%
Net Profit (Loss) for the Period
76.49%
Total assets
78.98%
Total equity
136.72%
Operating Profit Margin (ROS)
999.24%
Net Profit Margin
1065.54%
Return on Equity (ROE)
110.4%
Debt to Equity Ratio
-10.16%
Quick Ratio
2.75%
Cash Ratio
1.18%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?